The overall safety profiles of GLP-1 agonists and DPP-4 inhibitors are favorable, with a low incidence of hypoglycemia. This attribute, along with their weight and cardiovascular benefits, particularly with the GLP-1 agonists, make them appropriate choices in our 3 patient cases. Ongoing safety investigations with GLP-1 agonists and DPP-4 inhibitors will provide further clarity to the complete safety profiles of these agents.
|Original language||English (US)|
|Journal||Journal of Family Practice|
|Issue number||9 SUPPL. 1|
|State||Published - Sep 2010|
ASJC Scopus subject areas